pantoprazole has been researched along with Hepatocellular Carcinoma in 2 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Kataria, A | 1 |
Stolow, E | 1 |
Hubbard, H | 1 |
Matboli, M | 1 |
ElGwad, AA | 1 |
Hasanin, AH | 1 |
El-Tawdi, A | 1 |
Habib, EK | 1 |
Elmansy, RA | 1 |
Ibrahim, D | 1 |
Shehata, H | 1 |
Tash, F | 1 |
2 other studies available for pantoprazole and Hepatocellular Carcinoma
Article | Year |
---|---|
Pantoprazole-induced acute hepatocellular and cholestatic hepatitis.
Topics: Carcinoma, Hepatocellular; Hepatitis; Humans; Liver Neoplasms; Pantoprazole | 2022 |
Pantoprazole attenuates tumorigenesis via inhibition of exosomal secretion in a rat model of hepatic precancerous lesion induced by diethylnitrosamine and 2-acetamidofluorene.
Topics: 2-Acetylaminofluorene; Animals; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Diethyln | 2019 |